Hainan Huluwa Pharmaceutical Group Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 3/6
Hainan Huluwa Pharmaceutical Group's earnings have been declining at an average annual rate of -6.2%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 10.4% per year. Hainan Huluwa Pharmaceutical Group's return on equity is 9.9%, and it has net margins of 6.2%.
Anahtar bilgiler
-6.2%
Kazanç büyüme oranı
-8.2%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 10.9% |
| Gelir büyüme oranı | 10.4% |
| Özkaynak getirisi | 9.9% |
| Net Marj | 6.2% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Here's Why Hainan Huluwa Pharmaceutical Group (SHSE:605199) Has A Meaningful Debt Burden
Oct 23
Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Shares Climb 27% But Its Business Is Yet to Catch Up
Sep 25There's Reason For Concern Over Hainan Huluwa Pharmaceutical Group Co., Ltd.'s (SHSE:605199) Massive 27% Price Jump
Sep 25Risks To Shareholder Returns Are Elevated At These Prices For Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHSE:605199)
Jun 07Hainan Huluwa Pharmaceutical Group's (SHSE:605199) Shareholders Have More To Worry About Than Only Soft Earnings
May 03Gelir ve Gider Dağılımı
Hainan Huluwa Pharmaceutical Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 1,821 | 113 | 765 | 100 |
| 30 Jun 24 | 1,838 | 124 | 715 | 103 |
| 31 Mar 24 | 1,808 | 95 | 702 | 94 |
| 31 Dec 23 | 1,905 | 106 | 756 | 94 |
| 30 Sep 23 | 1,736 | 91 | 663 | 68 |
| 30 Jun 23 | 1,696 | 89 | 673 | 73 |
| 31 Mar 23 | 1,643 | 96 | 677 | 90 |
| 31 Dec 22 | 1,515 | 86 | 654 | 106 |
| 30 Sep 22 | 1,500 | 67 | 710 | 133 |
| 30 Jun 22 | 1,456 | 78 | 683 | 122 |
| 31 Mar 22 | 1,444 | 78 | 665 | 122 |
| 31 Dec 21 | 1,354 | 72 | 616 | 100 |
| 30 Sep 21 | 1,259 | 124 | 548 | 75 |
| 30 Jun 21 | 1,217 | 131 | 542 | 72 |
| 31 Mar 21 | 1,211 | 128 | 558 | 56 |
| 31 Dec 20 | 1,162 | 122 | 552 | 52 |
| 30 Sep 20 | 1,250 | 148 | 584 | 50 |
| 30 Jun 20 | 1,271 | 122 | 597 | 53 |
| 31 Mar 20 | 1,289 | 120 | 746 | 61 |
| 31 Dec 19 | 1,306 | 120 | 620 | 52 |
| 31 Dec 18 | 984 | 101 | 436 | 43 |
| 31 Dec 17 | 655 | 22 | 245 | 20 |
| 31 Dec 16 | 487 | 34 | 130 | 11 |
Kaliteli Kazançlar: 605199 has a large one-off gain of CN¥42.4M impacting its last 12 months of financial results to 30th September, 2024.
Büyüyen Kar Marjı: 605199's current net profit margins (6.2%) are higher than last year (5.3%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 605199's earnings have declined by 6.2% per year over the past 5 years.
Büyüme Hızlandırma: 605199's earnings growth over the past year (23.6%) exceeds its 5-year average (-6.2% per year).
Kazançlar vs. Sektör: 605199 earnings growth over the past year (23.6%) exceeded the Pharmaceuticals industry -1.2%.
Özkaynak Getirisi
Yüksek ROE: 605199's Return on Equity (9.9%) is considered low.